Evidence map›Paper›PMID 42318537›Full record

ArticleKidney international reports2026

Urinary Microcholesterol and Adverse Kidney Outcomes in CKD.

Hirotaka Furuta, Ryosuke Umeda, Masato Hoshi, Nanaka Morita, Fumiaki Sato, Hiroyuki Yokoi, Shun Minatoguchi, Soshiro Ogata, Kazuo Takahashi, Shigehisa Koide and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney international reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Hirotaka FurutaDepartment of Nephrology, Fujita Health University School of Medicine, 1-98, Kutsukakecho Dengakugakubo, Toyoake city, Aichi, Japan.
Ryosuke UmedaDepartment of Nephrology, Fujita Health University School of Medicine, 1-98, Kutsukakecho Dengakugakubo, Toyoake city, Aichi, Japan.
Masato HoshiDepartment of Disease Systems Analysis Medicine, Fujita Health University School of Health Sciences, Kutsukakecho Dengakugakubo 1-98, Toyoake city, Aichi, Japan.
Nanaka MoritaDepartment of Medical Science Technology, School of Health Science at Narita, International University of Health and Welfare, 4-3 Kozunomori, Narita 286-8686, Japan.
Fumiaki SatoDepartment of Disease Systems Analysis Medicine, Fujita Health University School of Health Sciences, Kutsukakecho Dengakugakubo 1-98, Toyoake city, Aichi, Japan.
Hiroyuki YokoiDepartment of Disease Systems Analysis Medicine, Fujita Health University School of Health Sciences, Kutsukakecho Dengakugakubo 1-98, Toyoake city, Aichi, Japan.
Shun MinatoguchiDepartment of Nephrology, Fujita Health University School of Medicine, 1-98, Kutsukakecho Dengakugakubo, Toyoake city, Aichi, Japan.
Soshiro OgataDepartment of Nephrology, Fujita Health University School of Medicine, 1-98, Kutsukakecho Dengakugakubo, Toyoake city, Aichi, Japan.
Kazuo TakahashiDepartment of Nephrology, Fujita Health University School of Medicine, 1-98, Kutsukakecho Dengakugakubo, Toyoake city, Aichi, Japan.
Shigehisa KoideDepartment of Nephrology, Fujita Health University School of Medicine, 1-98, Kutsukakecho Dengakugakubo, Toyoake city, Aichi, Japan.
Hiroyuki NaruseDepartment of Clinical Pathophysiology, Fujita Health University School of Health Sciences, Kutsukakecho Dengakugakubo 1-98, Toyoake city, Aichi, Japan.
Midori HasegawaDepartment of Nephrology, Fujita Health University School of Medicine, 1-98, Kutsukakecho Dengakugakubo, Toyoake city, Aichi, Japan.
Yukio YuzawaDepartment of Nephrology, Fujita Health University School of Medicine, 1-98, Kutsukakecho Dengakugakubo, Toyoake city, Aichi, Japan.
Hiroki HayashiDepartment of Nephrology, Fujita Health University School of Medicine, 1-98, Kutsukakecho Dengakugakubo, Toyoake city, Aichi, Japan.
Naotake TsuboiDepartment of Nephrology, Fujita Health University School of Medicine, 1-98, Kutsukakecho Dengakugakubo, Toyoake city, Aichi, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Urinary microcholesterol (U-mCHO) may reflect tubular or glomerular injury through impaired lipid handling; nonetheless, its prognostic value in chronic kidney disease (CKD) remains unclear. We examined whether U-mCHO is associated with adverse kidney outcomes. Methods: We conducted a cohort study of patients with CKD (baseline eGFR ≥ 15 ml/min per 1.73 m Results: A total of 1562 patients were included. The mean U-mCHO level was 3.0 ± 5.8 mg/g creatinine. Higher U-mCHO levels were associated with greater MAKE50 risk (adjusted hazard ratio [HR] for highest vs. lowest quartile: 7.30; 95% confidence interval [CI]: 2.74-19.49). This association was consistent when U-mCHO was modeled as a log-transformed continuous variable. The association remained consistent across subgroups and persisted in patients with low proteinuria (HR for MAKE30: 3.06; 95% CI: 1.37-6.85), with no interaction by proteinuria level ( Conclusion: U-mCHO is independently associated with MAKE50 in CKD. The association with MAKE30 was also observed in patients with low proteinuria, supporting U-mCHO as a potential noninvasive biomarker of kidney lipid injury.

Indexed as

chronic kidney diseaselipidsproteinuria

Identifiers

PMID42318537
PMCPMC13273664

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.